Is There a Role for Interleukin-2 Gene Transfer in the Management of Acute Leukemia?
The limitations encountered with the administration of high dose exogenous interleukin-2 (IL-2) have triggered the search for alternative immunotherapeutic approaches or delivery modalities. Studies carried out in experimental tumor models suggest that the tumor-genic potential can be reversed following transduction of different cytokine genes into the DNA of the neoplastic cells. Transfer of the IL-2 gene has also been associated with the generation of anti-tumor specificity and anti-tumor memory. These findings have led to the activation of the first clinical vaccination protocols with human tumor cells engineered to release IL-2 in patients suffering from different tumors. Here, we shall report on the feasability of inserting the IL-2 gene into human acute leukemia cells and the possibility of using this approach for the management of patients with acute leukemia.
KeywordsRenal Cell Carcinoma Acute Myeloid Leukemia Acute Leukemia Autologous Bone Marrow Transplantation Acute Leukemia Patient
Unable to display preview. Download preview PDF.
- 4.Foa R (1994):Does Interleukin-2 have a role in the management of acute leukemia? Journal of Clinical Oncology 11: 1817–1825Google Scholar
- 14.Meloni G, Foa R, Vignetti M et al (1994): Interleukin 2 may induce prolonged remissions in advanced acute myelogenous leukaemia. Blood, in pressGoogle Scholar
- 18.Soiffer RJ, Murray C, Cochran K et al (1982): Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell depleted allogeneic bone marrow transplanation. Blood 79: 517–526Google Scholar
- 23.Foa R, Guarini A; Gillio Tos A et al. (1991b): Peripheral blood and bone marrow immunophenotypic and functional modifications induced in acute leukemia patients treated with Interleukin 2: Evidence of in vivo lymphokine activated killer cell generation. Cancer Research 51: 964–968Google Scholar
- 25.Lissoni B, Barni S, Tancini G et al. (1994): A randomised study with subcutaneous low-dose interleukin-2 alone versus interleukin-2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma. British Journal of Cancer 69: 196–199PubMedCrossRefGoogle Scholar
- 28.Forni G, Parmiani G, Guarini A, Foa R (1994): Gene transfer in tumor therapy. Annals of Oncology, in pressGoogle Scholar
- 36.Guarini A; Gansbacher B, Cronin B et al. (1994): Specific T lymphocyte reactivity to IL-2 gene transduced human melanoma cells. In: Forni G, Foa R, Santoni A, Frati L (eds): Cytokine Induced Tumor Immunogenicity, London, UK: Academic Press, 403–413Google Scholar
- 38.Foa R, Fierro MT, Cesano A et al. (1991c): Defensive lymphokine-activated killer cell generation and activity in acute leukemia patients with active disease. Blood 78: 1041–1046Google Scholar